PMC6154838_01
Computed tomography (CT) and magnetic resonance imaging (MRI) scans from Patient 1. The CT scans show the right renal cell carcinoma (RCC) and left pheochromocytoma before (A, C) and after (B, D) sunitinib treatment. The MRI scans show the hemangioblastoma in the right cerebellum before sunitinib treatment (E) and the CT scan shows the site of the lesion after the operation (F). Red arrows indicate the masses.
kcbt-19-09-1470732-g001.jpg
PMC6154838_03_kcbt-19-09-1470732-g001.jpg
f0001
This scan revealed that the size of the RCC (Figure 1B) had decreased from 2.5 x 2.1 cm before sunitinib treatment to 1.1 x 0.9 cm after treatment. Similarly, the size of the left pheochromocytoma (Figure 1D) had decreased from 6.1 x 3.9 cm before sunitinib treatment to 3.3 x 2.4 cm after treatment (Table 2). A post-operative head CT scan confirmed complete resection of the tumor (Figure 1F).
PMC6154838_02
Computed tomography (CT) scans from Patient 2. The CT scans show multiple right renal cell carcinomas (RCCs) before and after sunitinib treatment, including the masses around the renal hilum (A and E), lower ventral (B and F), dorsal, lower dosal (C and G), superior pole (D and H). Red arrows indicate the masses.
kcbt-19-09-1470732-g002.jpg
PMC6154838_03_kcbt-19-09-1470732-g002.jpg
f0002
In Patient 2, all the masses in his right kidney decreased in size and iodine uptake after 4 months of sunitinib treatment (Figure 2E-H), as reported in Table 2.
PMC6154838_03
Computed tomography (CT) and magnetic resonance imaging (MRI) scans from Patient 1. The CT scans show the right renal cell carcinoma (RCC) and left pheochromocytoma before (A, C) and after (B, D) sunitinib treatment. The MRI scans show the hemangioblastoma in the right cerebellum before sunitinib treatment (E) and the CT scan shows the site of the lesion after the operation (F). Red arrows indicate the masses.
kcbt-19-09-1470732-g001.jpg
PMC6154838_03_kcbt-19-09-1470732-g001.jpg
f0001
This scan revealed that the size of the RCC (Figure 1B) had decreased from 2.5 x 2.1 cm before sunitinib treatment to 1.1 x 0.9 cm after treatment. Similarly, the size of the left pheochromocytoma (Figure 1D) had decreased from 6.1 x 3.9 cm before sunitinib treatment to 3.3 x 2.4 cm after treatment (Table 2). A post-operative head CT scan confirmed complete resection of the tumor (Figure 1F).
Computed tomography (CT) scans from Patient 2. The CT scans show multiple right renal cell carcinomas (RCCs) before and after sunitinib treatment, including the masses around the renal hilum (A and E), lower ventral (B and F), dorsal, lower dosal (C and G), superior pole (D and H). Red arrows indicate the masses.
kcbt-19-09-1470732-g002.jpg
PMC6154838_03_kcbt-19-09-1470732-g002.jpg
f0002
In Patient 2, all the masses in his right kidney decreased in size and iodine uptake after 4 months of sunitinib treatment (Figure 2E-H), as reported in Table 2.
Magnetic resonance imaging (MRI) and computed tomography (CT) scans from Patient 3. The MRI scans show multiple RCCs in the left kidney including RCC in the dorsal of the kidney (A and E), ventral of the kidney and beside the spine (B and F), as well as three pancreatic lesions (C and G) before and after sunitinib treatment. The CT scans show the lesion on her back before and after sunitinib treatment (D and H). Red arrows indicate the masses.
kcbt-19-09-1470732-g003.jpg
PMC6154838_03_kcbt-19-09-1470732-g003.jpg
f0003
Patient 3: In August 2011, a 50-year-old female was admitted to our hospital where a MRI scan revealed at least 3 lesions on her left kidney (Figure 3A and B) and 3 lesions in her pancreas (Figure 3C), which were most likely to be pancreatic NETs according to the characteristics on MRI scans. MRI scan on brain was negative and the abdominal CT scan discovered a mass with contrast enhancement on her back (Figure 3D) Five years ago before this admission, the patient had undergone a radical nephrectomy for the tumors on the right kidney. In Patient 3, the sizes of the RCCs in her left kidney and pancreatic lesions decreased, evidenced by the representative MRI scan after sunitinib treatment on August 2017 (Figure 3E-G), and remained stable through 6 years of follow-up. Interestingly, the sizes of the lesions on her back also decreased due to the treatment of sunitinib (Figure 3H).